Gender differences in long-term clinical outcomes after percutaneous coronary intervention of chronic total

Bimmer E Claessen1, Alaide Chieffo, George D Dangas

  • 1Cardiovascular Institute, Mount Sinai Medical Center, One Gustav L Levy Place, Box 1030, New York, NY 10029, USA.

Insights

Percutaneous coronary intervention for chronic total occlusion (CTO PCI) appears more beneficial for men than women. However, CTO PCI is safe and feasible for women and warrants further investigation.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Vascular Medicine

Background:

  • Gender differences in percutaneous coronary intervention (PCI) for chronic total occlusion (CTO) are not well understood.
  • CTO PCI is a complex procedure with limited data on outcomes stratified by sex.

Purpose of the Study:

  • To compare baseline characteristics, procedural success, and long-term clinical outcomes between men and women undergoing CTO PCI.
  • To evaluate the impact of gender on the benefits of successful CTO PCI.

Main Methods:

  • A retrospective analysis of 1791 patients (1852 CTOs) who underwent CTO PCI across three international centers (1998-2007).
  • Comparison of baseline demographics, procedural success (residual stenosis <50%), and 5-year clinical event rates (mortality, need for coronary artery bypass graft surgery, major adverse cardiac events) between male and female patients.

Main Results:

  • Women constituted 14% of the study population.
  • Procedural success rates were similar between genders, but successful CTO PCI was associated with a greater reduction in major adverse cardiac events (MACE) in men compared to women.
  • Successful CTO PCI reduced mortality and the need for coronary artery bypass graft (CABG) surgery in men, with a trend towards reduced CABG need in women.

Conclusions:

  • Successful CTO PCI demonstrated a greater benefit in reducing MACE for men compared to women.
  • CTO PCI is safe and feasible in women, suggesting it should be considered more frequently.
  • Further randomized controlled trials are necessary to precisely ascertain the impact of CTO PCI in both genders.
Abstract

Related Concept Videos

Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...